Research graph
References from Less is more: the role of preoperative ultrasound as a risk stratifying tool in identifying low volume axillary disease in breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Axillary surgery in breast cancer: an updated historical perspective
10.1053/j.seminoncol.2020.09.001 · 2020 · External reference
Complications of axillary lymph node dissection in treatment of early breast cancer: a comparison of MRM and BCS
10.1007/s13193-011-0078-2 · 2011 · External reference
Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial
10.1001/jama.2017.11470 · 2017 · External reference
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
10.1016/s1470-2045(14)70460-7 · 2014 · External reference
Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer
10.1001/jamasurg.2023.1772 · 2023 · External reference
Omitting axillary dissection in breast cancer with sentinel-node metastases
10.1056/nejmoa2313487 · 2024 · External reference
Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial
10.1245/s10434-022-11866-w · 2022 · External reference
Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer
10.1016/j.suronc.2022.101823 · 2022 · External reference
Ten-year oncologic outcomes in T1-3N1 breast cancer after targeted axillary sampling: a retrospective study
10.1245/s10434-023-13191-2 · 2023 · External reference
The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis
10.3390/cancers13071539 · 2021 · External reference
Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients 'on behalf of the group of surgeons from the French Unicancer Federation
10.1093/annonc/mdr355 · 2012 · External reference
Current axillary management of patients with early breast cancer and low-volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey
10.1007/s10549-024-07328-4 · 2024 · External reference
Axillary nodal burden in primary breast cancer patients with positive pre-operative ultrasound guided fine needle aspiration cytology: management in the era of ACOSOG Z011
10.1016/j.ejso.2015.01.011 · 2015 · External reference
Meta-analysis of tumor burden in pre-operative axillary ultrasound positive and negative breast cancer patients
10.1007/s10549-017-4405-3 · 2017 · External reference
Axillary tumor burden in women with one abnormal node on ultrasound compared to women with multiple abnormal nodes
10.1016/j.crad.2017.12.014 · 2018 · External reference
Abstract P3-08-16: TADPOLE: a multicentre, pragmatic, phase III randomised controlled trial comparing targeted axillary dissection vs axillary node clearance in patients with POsitive axillary lymph nodes in early breast cancer
10.1158/1557-3265.sabcs24-p3-08-16 · 2025 · External reference
Non-invasive predictors of axillary lymph node burden in breast cancer: a single-institution retrospective analysis
10.1007/s10549-022-06672-7 · 2022 · External reference
The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
10.3322/caac.21388 · 2017 · External reference
Determining whether high nodal burden in early breast cancer patients can be predicted preoperatively to avoid sentinel lymph node biopsy
10.4048/jbc.2019.22.e8 · 2019 · External reference
Ultrasound staging in breast cancer: a decision-making oriented approach to axillary metastatic burden prediction
10.1016/j.suronc.2020.08.020 · 2020 · External reference
Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice
10.1016/j.breast.2012.09.003 · 2013 · External reference
Relation between tumor size and lymph node metastasis according to subtypes of breast cancer
10.4048/jbc.2021.24.e4 · 2021 · External reference
Axillary staging is not justified in postmenopausal clinically node-negative women based on nodal disease burden
10.1245/s10434-022-12203-x · 2023 · External reference
The relationship between tumor size, nodal status and distant metastases: on the origins of breast cancer
10.1007/s10549-018-4796-9 · 2018 · External reference
A study correlating the tumor site and size with the level of axillary lymph node involvement in breast cancer
10.4103/njs.njs_47_19 · 2020 · External reference
Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study
10.1038/s41598-024-84115-7 · 2025 · External reference
Prediction of high nodal burden with ultrasound and magnetic resonance imaging in clinically node-negative breast cancer patients
10.1186/s40644-019-0191-y · 2019 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2019 · External reference
Axillary tumor burden in women with a fine-needle aspiration/core biopsy-proven positive node on ultrasonography compared to women with a positive sentinel node
10.1002/bjs.10661 · 2017 · External reference
Does preoperative axillary staging lead to overtreatment of women with screen-detected breast cancer?
10.1016/j.crad.2017.11.023 · 2018 · External reference
Positive ultrasound-guided lymph node needle biopsy in breast cancer may not mandate axillary lymph node dissection
10.1245/s10434-017-5935-y · 2017 · External reference
A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients
10.1097/sla.0000000000004572 · 2022 · External reference
ATNEC: a multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy
10.1200/jco.2022.40.16_suppl.tps615 · 2022 · External reference
